Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Sell
45
IRWD Quote, Financials, Valuation and Earnings
Last price:
$3.21
Seasonality move
:
-12.63%
Day range:
$3.14 - $3.24
52-week range:
$0.53 - $4.78
Dividend yield:
0%
P/E ratio:
20.71x
P/S ratio:
1.60x
P/B ratio:
--
Volume:
765.9K
Avg. volume:
2.5M
1-year change:
-30.28%
Market cap:
$520.6M
Revenue:
$351.4M
EPS (TTM):
$0.15
Analysts' Opinion
-
Consensus RatingIronwood Pharmaceuticals, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $2.50, Ironwood Pharmaceuticals, Inc. has an estimated downside of -21.88% from its current price of $3.20.
-
Price Target UpsideAccording to analysts, the highest upside price target is $3.80 representing -100% upside increase from its current price of $3.20.
Fair Value
-
According to the consensus of 4 analysts, Ironwood Pharmaceuticals, Inc. has -21.88% downside to fair value with a price target of $2.50 per share.
IRWD vs. S&P 500
-
Over the past 5 trading days, Ironwood Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.19% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ironwood Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ironwood Pharmaceuticals, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Ironwood Pharmaceuticals, Inc. reported revenues of $122.1M.
Earnings Growth
-
Ironwood Pharmaceuticals, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Ironwood Pharmaceuticals, Inc. reported earnings per share of $0.23.
Enterprise value:
978.4M
EV / Invested capital:
2.93x
Price / LTM sales:
1.60x
EV / EBIT:
6.72x
EV / Revenue:
2.89x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.46x
Price / Operating cash flow:
7.99x
Enterprise value / EBITDA:
6.64x
Gross Profit (TTM):
$337.1M
Return On Assets:
8.16%
Net Income Margin (TTM):
8.7%
Return On Equity:
--
Return On Invested Capital:
9.89%
Operating Margin:
63.64%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $432.4M | $378.4M | $339M | $91.6M | $122.1M | |
| Gross Profit | $431M | $376.4M | $337.1M | $91.1M | $121.6M | |
| Operating Income | $197.4M | $117.1M | $145.5M | $34.2M | $77.7M | |
| EBITDA | $198.8M | $119.1M | $147.4M | $34.7M | $78.2M | |
| Diluted EPS | -$6.24 | -$0.02 | $0.15 | $0.02 | $0.23 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $695.4M | $699M | $253.6M | $178.6M | $273.8M | |
| Total Assets | $1.1B | $1B | $524.1M | $389.5M | $396.1M | |
| Current Liabilities | $145.7M | $27.1M | $280.6M | $49.4M | $242.5M | |
| Total Liabilities | $499.4M | $449.3M | $849.7M | $700.9M | $660.2M | |
| Total Equity | $579.9M | $591.1M | -$325.7M | -$311.3M | -$264.2M | |
| Total Debt | $470.1M | $412.9M | $737.5M | $611.7M | $595M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $226.8M | $124.2M | $67.7M | $9.9M | $47.6M | |
| Cash From Investing | -$1B | -$4.3M | -$35K | -$16K | -$2K | |
| Cash From Financing | $330.9M | -$143M | -$14.8M | -$27.2M | -- | |
| Free Cash Flow | $226.7M | $123.8M | $67.6M | $9.9M | $47.6M | |
IRWD
Sector
Market Cap
$520.6M
$28.2M
Price % of 52-Week High
67.02%
50.25%
Dividend Yield
0%
0%
Shareholder Yield
3.8%
-1.54%
1-Year Price Total Return
-30.28%
-18.1%
Beta (5-Year)
0.177
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.28
200-day SMA
Buy
Level
$1.45
Bollinger Bands (100)
Buy
Level
1.07 - 2.99
Chaikin Money Flow
Sell
Level
-5.5M
20-day SMA
Sell
Level
$3.46
Relative Strength Index (RSI14)
Sell
Level
49.07
ADX Line
Buy
Level
39.71
Williams %R
Buy
Level
-84.4156
50-day SMA
Buy
Level
$2.78
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Neutral
Level
14.9M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7281)
Sell
CA Score
(Annual)
Level (-4.9926)
Buy
Beneish M-Score
(Annual)
Level (-4.3298)
Sell
Momentum Score
Level (1)
Buy
Ohlson Score
Level (-602.7312)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. It operates through the Human Therapeutics segment. The company was founded on January 5, 1998 and is headquartered in Boston, MA.
Stock Forecast FAQ
In the current month, IRWD has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The IRWD average analyst price target in the past 3 months is $2.50.
-
Where Will Ironwood Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ironwood Pharmaceuticals, Inc. share price will drop to $2.50 per share over the next 12 months.
-
What Do Analysts Say About Ironwood Pharmaceuticals, Inc.?
Analysts are divided on their view about Ironwood Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ironwood Pharmaceuticals, Inc. is a Sell and believe this share price will rise from its current level to $0.70.
-
What Is Ironwood Pharmaceuticals, Inc.'s Price Target?
The price target for Ironwood Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $2.50 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is IRWD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ironwood Pharmaceuticals, Inc. is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of IRWD?
You can purchase shares of Ironwood Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ironwood Pharmaceuticals, Inc. shares.
-
What Is The Ironwood Pharmaceuticals, Inc. Share Price Today?
Ironwood Pharmaceuticals, Inc. was last trading at $3.21 per share. This represents the most recent stock quote for Ironwood Pharmaceuticals, Inc.. Yesterday, Ironwood Pharmaceuticals, Inc. closed at $3.20 per share.
-
How To Buy Ironwood Pharmaceuticals, Inc. Stock Online?
In order to purchase Ironwood Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get IRWD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
IRWD
Sector
P/E ratio
20.71x
23.92x
PEG ratio
--
-0.01x
P/B ratio
--
1.83x
Price / LTM sales
1.60x
1.61x
Growth Metrics
IRWD
Sector
Revenue growth
33.27%
4.6%
Earnings growth
906.14%
10.88%
Revenue (5-year growth)
-3.89%
6.46%
Earnings forecast
$0.12
-$0.21
Profitability
IRWD
Sector
Profitability FY 2024
$349.4M
$3.5M
Return on invested capital
9.89%
-31.84%
Return on assets
8.16%
-27.96%
Return on equity
--
-37.63%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
9
Balance Sheet
IRWD
Sector
Total cash
$140.4M
$26.3M
Short term investments
--
$25.7M
Total assets
$350.9M
$76.9M
Long term debt
$595M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
